AllDocs -> cancers

Arsenic-Related Chromosomal Alterations in Bladder Cancer Lee E. Moore, Allan H. Smith, Clarence Eng, David Kalman, Sandy DeVries, Vivek Bhargava, Karen Chew, Dan Moore II, Catterina Ferreccio, Omar A. Rey, Frederic M. Waldman Background: Previous studies have demonstrated that inges- tion of arsenic in drinking water is a strong risk factor for several forms of cancer , including bladder cancer . It is not known whether arsenic-related cancers are genetically simi- lar to cancers in unexposed individuals or what mechanisms of carcinogenesis may underlie their formation. This study was designed to compare chromosomal alterations in blad- der cancers of arsenic-exposed individuals to provide insight into the mechanism of how arsenic may induce or promote cancer . Methods: A case–case study was conducted in Ar- gentina and Chile examining ...

Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression Ichabod Jung, MD, and Edward Messing, MD Background: The basis for bladder cancer development and progression is complex and involves genetic abnormalities. These abnormalities yield phenotypic changes that allow normal transitional cells to become cancerous and finally acquire the “malignant phenotype.” Methods: The authors review the most common genetic alterations in bladder cancer and the molecular mechanisms and pathways involved in the conversion of normal transitional cell into malignant transitional cancer cells. Results: There are several potential genetic changes of the urothelium that eventually cause bladder cancer initiation and tumor progression. Some of these alterations are also found in other malignancies suggesting that key common pathways exist in the ...

381 Am J Epidemiol 2004;159:381–389 American Journal of Epidemiology Copyright © 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 159, No. 4 Printed in U.S.A. DOI: 10.1093/aje/kwh054 Case-Control Study of Bladder Cancer and Exposure to Arsenic in Argentina Michael N. Bates 1 , Omar A. Rey 2 , Mary L. Biggs 3 , Claudia Hopenhayn 4 , Lee E. Moore 5 , David Kalman 6 , Craig Steinmaus 1 , and Allan H. Smith 1 1 Arsenic Health Effects Research Group, School of Public Health, University of California, Berkeley, CA. 2 Facultad de Medicina, Universidad Catolica de Córdoba, Córdoba, Argentina. 3 Arsenic Health Effects Research Group, School of Public Health, ...

Because bladder cancer is not widely discussed, you may believe that it is a rare disease. Yet this form of cancer occurs more often than you might think. In fact, it is the fourth most common cancer among men and the ninth most common among women in the United States. Each year, more than 50,000 new cases of bladder cancer are detected. Fortunately, the majority of bladder cancers do not grow rapidly and can be treated without major surgery. Thus, most patients with bladder cancer are not at risk of developing a cancer that will spread and become life-threatening. Early detection is vital; it allows the prompt treatment that gives patients the best chance for a favorable outlook. This booklet is designed to answer your questions about bladder cancer - what it is, what its signs are, how it is treated, and what you can do to help keep your bladder healthy. ...

MDACC Bladder Cancer (Transitional Cell Ca) (Page 1 of 2) TREATMENTS FOLLOW-UP INITIAL SCREEN STAGING INITIAL DIAGNOSIS Developmtent Credits Cystoscopy TUR IVP EUA CXR CT Pelvis Muscle in Pathology Specimen? Mitomycin OR BCG (6 weeks) +/- maintenance OR Clinical Trial BCG (6 weeks) + maintenance OR Clinical Trial TUR and Surveillance Cystoscopy (q3mos for 4 yrs; q4mos for 3 yrs; q6mos for 2 yrs; then annually) Consider rebiopsy to exclude T2 Repeat cystoscopic biopsy to assess response Repeat cystoscopy to assess response (+/- biopsy if indicated) Residual disease? Residual disease? Continued Surveillance Cystoscopy (q3mos for 4 yrs; q4mos for 3 yrs; q6mos for 2 yrs; then annually) Patient accepts ...

MDACC Suspicion of Bladder Cancer Clinical presentation: Hematuria and/or persistent irritative symptoms (e.g., pain, frequency) Urinalysis Urine culture Treat infection Positive culture Negative for blood Negative culture Negative for blood Positive culture Positive for blood Continue ongoing care with primary care physician Cystoscopy positive? (v1.1;4/99;2/29/00) Negative (with or without hematuria) Positive No Refer to Bladder Cancer Practice Guideline Persistent irritative symptoms? Persistent irritative symptoms? Positive for blood? Treat infection Repeat urinalysis Yes Continue ongoing care with primary care physician No Yes Yes No Yes Repeat cystoscopy with random biopsy ...

CIGARETTE SMOKING AND BLADDER CANCER IN MEN: A POOLED ANALYSIS OF 11 CASE-CONTROL STUDIES Paul B RENNAN 1 *, Olivier B OGILLOT 1 , Sylvaine C ORDIER 2 , Eberhard G REISER 3 , Walter S CHILL 3 , Paolo V INEIS 4 , Gonzalo L OPEZ -A BENTE 5 , Anastasia T ZONOU 6 , Jenny C HANG -C LAUDE 7 , Ulrich B OLM -A UDORFF 8 , Karl-Heinz J ¨ OCKEL 9 , Francesco D ONATO 10 , Consol S ERRA 11 , Jorgen W AHRENDORF 7 , Martine H OURS 12 , Andrea T’M ANNETJE 1 , Manolis K OGEVINAS ...

Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro Jinsoo Chung a , Cheol Kwak b,c , Ren Jie Jin d , Chang-Ho Lee e , Kang Hyun Lee a , Sang Eun Lee b,f, * a Urologic Oncology Clinic, National Cancer Center, Goyang, South Korea b Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, South Korea c Clinical Research Institute, Seoul National University Hospital, 28 Yongon Dong, Jongno Ku, Seoul, 110-744, Seoul, South Korea d Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA e Department of Urology, Soonchunhyang University College of Medicine, Cheonan, South Korea ...

Prudential Financial is a service mark of The Prudential Insurance Company of America, Newark, NJ and its affiliates The Prudential Insurance Company of America 751 Broad Street, Newark, NJ 07102-3777 RX50 DOC IFS-A010754, Ed. 04/02, Exp. 10/11/03 116 Bladder Cancer Approximately 54,000 new cases of bladder cancer are diagnosed annually resulting in 12,000 deaths in the U.S. Men are affected three times more frequently than women, but it is rare in individuals who are younger than 40. Those demonstrating an increased risk are smokers and workers in the dye, chemical, and rubber industries. The tumors have a tendency to recur following removal and may become more invasive with each recurrence. The major prognostic features are the depth of invasion into the bladder wall (stage) and the degree of cellular differentiation of the tumor (grade). A deeper level of invasion ...

Health Consultation Review of Bladder Cancer Data (May, 2001) Abstract This report is a follow-up to the November 1998 study Cancer Incidence and Birthweight in Relation to Exposure to Raymark Waste. It was undertaken in response to citizens’ concerns about elevated female bladder cancer rates among those who lived closer to Raymark waste. The report re-analyzed data from the original study, taking into account an additional five years of bladder cancer data (1991-1996). New techniques were used to improve statistical precision and more advanced disease mapping methodologies were also employed. The results of this report are therefore believed to be more accurate than the original study. The report found that there were elevated risks for female bladder cancer near Raymark waste sites, but this did not hold true over time. Male bladder cancer was not consistently ...

Dr Willem Oosterlinck is currently Chairman of the Superficial Bladder Cancer Committee of the European Organisation for Research and Treatment of Cancer (EORTC) and heads the Department of Urology at the University Hospital Ghent in Belgium. Formerly President of the Belgian Society of Urology (BVU) and the Belgian Congress of Urology, he is currently a member of the Accreditation Commission for Urology of the Ministry of Health, the European Urological Association (EAU), The Société Internationale d’Urologie (SIU) and BVU. Dr Oosterlinck was also Chairman of the committee responsible for development of guidelines on superficial bladder tumours in the EAU. He began his career at the University Hospital Ghent as a Senior Assistant in Urology and advanced to Adjunct Director of the Department of Urology, prior to earning his current position. ...

1193 Am J Epidemiol 2003;158:1193–1201 American Journal of Epidemiology Copyright © 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 12 Printed in U.S.A. DOI: 10.1093/aje/kwg281 Case-Control Study of Bladder Cancer and Drinking Water Arsenic in the Western United States Craig Steinmaus 1 , Yan Yuan 2 , Michael N. Bates 2 , and Allan H. Smith 2 1 Division of Occupational and Environmental Medicine, University of California, San Francisco, CA. 2 School of Public Health, University of California, Berkeley, CA. Received for publication November 13, 2002; accepted for publication June 23, 2003. Numerous epidemiologic investigations have identified links between high concentrations of arsenic in drinking water and cancer , although ...

Chapter 9: Bladder cancer 91 Bladder cancer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

European Association of Urology GUIDELINES ON BLADDER CANCER Willem Oosterlinck, Gerhard Jakse, Per-Uno Malmström, Michael Stöckle, Cora Sternberg, David Neal, Fernando Calais da Silva Page 2 1. BACKGROUND The incidence of bladder carcinoma is rising in western countries. In 1996, approximately 53,000 patients were diagnosed with bladder cancer in the USA (1), 9000 in France (2), 2000 in Sweden (3) 8000 in Spain (4) and 1120 in Belgium (5). Approximately 75 to 85 % of patients present with disease confined to the mucosa (stage Ta-Tis) or submucosa (stage T1). The other 15 to 25 % have muscle invasion or nodal disease (stages T2-4, N+) at presentation (1). The management of superficial bladder cancer has become more complex, with urologic opinion differing with regard to initial investigation, treatment and follow-up. ...

Anterior Urethral Recurrence of Superficial Bladder Cancer : Its Clinical Significance Takashi Saika , Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata, Haruki Kaku, Naoki Akebi, Nobuyuki Kusaka, and Hiromi Kumon Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan The aim of this study was to reveal the clinical features of anterior urethral recurrence in patients with superficial bladder cancer , and to determine the appropriate treatment. Three hundred and three patients with superficial bladder cancer , who were newly diagnosed and initially treated conservatively in our hospital between 1965 and 1990, were followed for at least 5 years and their clinical outcomes were analyzed. Clinical factors, including anterior urethral recurrence, were evaluated statistically regarding tumor progression. Eight patients (2.6 ) had anterior urethral ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Bladder Cancer and Exposure to Ionizing Radiation 1 Bladder Cancer and Exposure to Ionizing Radiation Summary: There is strong evidence that bladder cancer may be associated with exposure to ionizing radiation. This evidence includes studies of nuclear workers. This is consistent with the National Research Council’s finding that the bladder is sensitive to ionizing radiation. Bladder cancer is designated as a “specified” cancer under the Energy Employees Occupational Illness Compensation Program Act. Historically, incidence of bladder cancer has been high in both Los Alamos County and Rio Arriba County. Mortality has been very low in Los Alamos County and moderate in Rio Arriba County. Incidence means new cases of cancer ...

RESOURCE SUPPORT For additional information about bladder cancer , the following resources are available: National Cancer Institute Cancer Information Service (CIS) 1-800-4- CANCER Cancernet www.cancernet.nci.nih.gov The Cancer Information Service (CIS) and Cancernet are National Cancer Institute programs that provide a nationwide telephone service and web site for cancer patients, their families and friends. American Cancer Society 1-800-ACS-2345 www. cancer .org The American Cancer Society (ACS) is a voluntary organization with a national office in Atlanta, Georgia, and local facilities across the country. It supports research, patient education programs, and other services for family members. It also publishes and distributes free booklets on colon cancer and home care. AmeriPath, Inc. www.ameripath.com AmeriPath, Inc., is a ...

Brochure More information from http://www.researchandmarkets.com/reports/6315 Title of Clinical Trials for Bladder Cancer Description: Database Table: Title of Clinical Trials for Bladder Cancer Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology and healthcare sectors. Over 600 database tables are now available from Research and Markets A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: ...

Brochure More information from http://www.researchandmarkets.com/reports/6025 Drugs Used in Bladder Cancer Therapy Description: Database Table: Drugs Used in Bladder Cancer Therapy Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology and healthcare sectors. Over 600 database tables are now available from Research and Markets A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: ...

Brochure More information from http://www.researchandmarkets.com/reports/6023 Drugs in Development for Bladder Cancer Description: Database Table: Drugs in Development for Bladder Cancer Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology and healthcare sectors. Over 600 database tables are now available from Research and Markets A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: ...

For Internal Use Only. Not For Use With The Public. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Prudential Financial and the Rock logo are registered service marks of The Prudential Insurance Company of America and its affiliates The Prudential Insurance Company of America 751 Broad Street, Newark, NJ 07102-3777 RX50 DOC IFS-A010754, Ed. 10/03, Exp. 04/05 Bladder Cancer Approximately 56,500 new cases of bladder cancer are diagnosed annually resulting in 12,600 deaths in the U.S. Men are affected more frequently than women, but it is rare in individuals who are younger than 40. Those demonstrating an increased risk are smokers and workers in the dye, chemical, and rubber industries. The tumors have a tendency to recur following removal and may become more invasive with each recurrence. The major prognostic features ...

Leaflet No 8601601 04/03/98 NBCA 1 Reviewed 2/03 Information for patients with newly diagnosed bladder cancer Urology Department Information prepared by Mrs Sue Cumisky Nurse Practitioner Urology East Somerset NHS Trust (01935) 384394 Further information for people with cancer is available on request or may be obtained by contacting: Macmillan cancer relief 0845 6016161 or CancerBACUP 0800 18 11 99 Page 2 At your cystoscopy today, a growth has been found which is likely to be malignant ( cancer ). Bladder cancers grow like warts on the lining of the bladder . As they develop, they can put down deeper roots which may affect the muscular wall of the bladder . In the early stages, the cancer is easy to treat and the condition can be monitored by regular ...

The highest average annual age-adjusted incidence rate for the 1992-96 period was among white males (34.7 per 100,000). This is compared to 17.7 for black males and 8.8 for all females. Pennsylvania's 1992-96 incidence rate for white males is comparable to the National Cancer Institute's average annual SEER rate of 31.3 for 1992-96. There were 3,354 new cases of urinary bladder cancer reported for Pennsylvania residents in 1996, the second highest annual number ever reported to the Pennsylvania Cancer Registry. The annual age-adjusted incidence rates from 1987 to 1996 have been slightly higher in recent years for black males and white females. Annual incidence rates for white males and black females remained fairly stable over that ten-year period. White males had the highest average annual age-specific incidence rates during 1992-96 for almost every age-group. The role of cigarette smoking as an important cause of bladder ...

1 Bladder cancer Pathogenesis and the biological significance of affected FGFR3 and P53 pathways Ellen C. Zwarthoff Course Oncogenesis and Tumor Biology 27-31 October 2003 Graduate School Molecular Medicine Contents • Bladder cancer : introduction • Bladder cancer genetics • Mutations in the FGFR3 and P53 genes • Use of molecular markers in diagnosis • Conclusions Robbins, 6 th ed. Slide 8.20 Bladder cancer : introduction Types of urothelial cancer (> 90% bladder cancer ) • Transitional cell carcinoma (90%): • Squamous cell carcinoma (5%) • Adenocarcinoma (5%) Bladder cancer : introduction Robbins, 6 th ed. Slide 22.11 Urothelial tumors: grading WHO ...

Bladder Cancer : Underwriting Perspective Underwriting Questions and Answers Bladder cancer is common malignancy of the transitional cells lining the surface of the bladder . There were approximately 56,000 new cases of bladder cancer diagnosed in 2002. There were over 12,000 deaths from bladder cancer in 2002. Bladder cancer is usually diagnosed in person 40 and older, with men being 2-3 times more likely to be affected. The primary risk factor for bladder cancer is smoking. Cigarette smoking has been shown to increase the risk of developing bladder cancer by a factor of five when compared to non-smokers. 50% of men diagnosed with bladder cancer are smokers. 30% of women diagnosed with bladder cancer are smokers. The most common symptom of bladder cancer is blood in the urine, called hematuria. The work up for ...

Gene Discovery in Bladder Cancer Progression using cDNA Microarrays Marta Sanchez-Carbayo,* Nicholas D. Socci, † Juan Jose Lozano, ‡ Wentian Li, § Elizabeth Charytonowicz,* Thomas J. Belbin, † Michael B. Prystowsky, † Angel R. Ortiz, ‡ Geoffrey Childs, † and Carlos Cordon-Cardo* From the Division of Molecular Pathology, * Memorial Sloan- Kettering Cancer Center, New York; the Departments of Molecular Genetics and Pathology and the Seaver Center for Bioinformatics, † Albert Einstein College of Medicine, Bronx; the Department of Physiology and Biophysics, ‡ Mt. Sinai School of Medicine, New York; and the Center for Genomics and Human Genetics, § North Shore-Long Island Jewish Research Institute, Manhasset, New ...

LifePro Financial Services Inc. 225 West Plaza – Solana Beach, CA 92075 – PH: 888-543-3776 – FAX: 858-793-4981 – Email: greg@lifepro.net Cancer – Bladder LifePro Finacial Services, Inc. – Phone: 888-543-3776 – FAX: 858-793-4981 – email: greg@lifepro.net Proposed Insured Name: M F Date of Birth or Age Face Amount: __ Max. Premium; $__/yr. UL WL Term Survivorship Do you currently smoke cigarettes? Y N If no, did you ever smoke: Never Quit (Date): Do you currently use any other tobacco products (i.e. nicotine patches, cigars, pipe, chew): Y N If yes, please provide details: When did you last use any form of tobacco:__(Month) __(Year) Type used last: (1) Date or age of diagnosis: (2) Date of last treatment: (3) What type of treatment was performed? Surgery Radiation Chemotherapy (2) How often does the proposed insured visit their physician for follow-up? Monthly Every 3 ...